Physician profile
Brittany Walker
NPI 1467203851
$2,853.02
in general payments reported to CMS, 2019-2025
28 companies · $2,364 in 2025
The $2,364 reported for 2025 was more than what 96% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2024: $489 · 2025: $2,364.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,853.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,853.02 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $508.46 | 2024-2025 | |
| Ucb, INC. | $309.78 | 2024-2025 | Rystiggo, Fintepla, Zilbrysq |
| Teva Pharmaceuticals USA, INC. | $238.47 | 2025 | Austedo Xr |
| Vanda Pharmaceuticals INC. | $194.75 | 2025 | Ponvory, Fanapt, Hetlioz |
| Pfizer INC. | $158.54 | 2024-2025 | |
| Novartis Pharmaceuticals Corporation | $156.99 | 2024-2025 | |
| Alexion Pharmaceuticals, INC. | $122.39 | 2024-2025 | Ultomiris |
| Takeda Pharmaceuticals U.S.A., INC. | $113.51 | 2025 | Hyqvia |
| Emd Serono, INC. | $110.86 | 2024-2025 | |
| Otsuka America Pharmaceutical, INC. | $99.49 | 2024-2025 | Rexulti |
| Catalyst Pharmaceuticals, INC. | $88.81 | 2024-2025 | |
| Neurelis, INC. | $87.44 | 2025 | Valtoco |
| Merz Pharmaceuticals, LLC | $86.72 | 2025 | Inbrija |
| Eisai INC. | $85.69 | 2024-2025 | |
| Lilly USA, LLC | $72.67 | 2024-2025 | Kisunla, Amyvid |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $59.84 | 2025 | |
| Ipsen Biopharmaceuticals, INC | $55.71 | 2025 | Dysport |
| Tg Therapeutics, INC. | $54.48 | 2024 | |
| Sk Life Science, INC. | $50.98 | 2024-2025 | |
| Aucta Pharmaceuticals, INC. | $35.38 | 2025 | Motpoly Xr |
| Alnylam Pharmaceuticals INC. | $25.97 | 2024 | Onpattro |
| Axsome Therapeutics, INC. | $23.82 | 2025 | Symbravo |
| Genentech USA, INC. | $22.72 | 2025 | Ocrevus Zunovo |
| Lundbeck LLC | $20.97 | 2025 | Vyepti |
| Grifols USA, LLC | $20.69 | 2025 | Gamunex-C |
| Azurity Pharmaceuticals, INC. | $18.17 | 2024 | Horizant |
| Amneal Pharmaceuticals LLC | $16.40 | 2024 | Ongentys 50mg Capsules 30 |
| Exact Sciences Corporation | $13.32 | 2024 | Cologuard Collection Kit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brittany Walker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.